Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity

Infection and Immunity

Volumn 70, Issue 7, 2002, Pages 3752-3758

  Drogari Apiranthitou, M ^a   Kuijper, E J ^a   Dekker, N ^a   Dankert, J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; CHIMERIC ANTIBODY; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MUTANT PROTEIN; PORIN; PROTEIN PLAK33; UNCLASSIFIED DRUG;

ARTICLE; BACTERIOLYSIS; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; DOSE RESPONSE; ENCAPSULATION; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SERUM BACTERICIDAL ACTIVITY;

ANTIBODIES, BACTERIAL; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; HUMANS; NEISSERIA MENINGITIDIS; PORINS;

EID: 0036081311     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.7.3752-3758.2002     Document Type: Article

References (50)

1. Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae
2. Dynamics of meningococcal carrier state and characterisation of the carrier strains: A longitudinal study within three cohorts of military recruits
3. Damage to mammalian cells by proteins that form transmembrane pores
4. Complement S-protein (vitronectin) is associated with cytolyric membrane-bound C5b-9 complexes
5. Functions and relevance of the terminal complement sequence
6. The Stonehouse survey: Nasopharyngeal carriage of meningococci and Neisseria lactamica
7. Meningococcal carriage and disease
8. Immunogenicity and reactogenicity in UK infants of a novel vesicle vaccine containing multiple class 1 (PorA) outer-membrane proteins
9. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age
10. Infectious disease associated with complement deficiencies
11. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine
12. Assessment of complement deficient persons among patients with meningococcal disease in the Netherlands
13. An IgG monoclonal antibody to group B meningococci cross-reacts with the developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues
14. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes
15. Human immunity to the meningococcus. I. The role of humoral antibodies
16. Human immunity to the meningococcus. II. Development of natural immunity
17. Analysis of C3 deposition and degradation on bacterial surfaces after opsonization
18. Activation of complement by serum-resistant Neisseria gonorrhoeae. Assembly of the membrane attack complex without subsequent cell death
19. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation
20. Alalysis of C3 deposition and degradation on Neisseria meningitidis and Neisseria gonorrhoeae
21. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion
22. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane
23. Studies on the mechanism of bacterial resistance to complement-mediated killing IV. C5b-9 forms high molecular weight complexes with bacterial outer membrane constituents on serum resistant but not on serum-sensitive Neisseria gonorrhoeae
24. Multimeric C9 within C5b-9 deposits in unique locations in the cell wall of Salmonella typhimurium
25. Epidemiology of meningococcal disease in Europe and the USA
26. The (α2→8)-linked polysialic acid capsule and lipo-oligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum
27. Ba and Bb fragments of factor B activation: Fragment production, biological activities, neoepitope expression and quantification in clinical samples
28. Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial polysaccharides and with lipid A
29. Antibody independent killing of gram-negative bacteria via the classical pathway of complement
30. Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model
31. Aeromonas salmonicida resistance to complement-mediated killing
32. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer-membrane protein vaccine: Comparison with efficacy
33. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma
34. Complement
35. Phase I clinical trial with a hexavalent PorA containing meningococcal outer-membrane vesicle vaccine
36. Immunogenicity of two efficacious outer-membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland
37. Membrane attack by complement
38. The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B N. meningitidis
39. Human antibody responses to meningococcal outer-membrane antigens after three doses of the Norwegian group B meningococcal vaccine
40. Complement deficiency states and infection
41. Meningitis bacterium is viable without endotoxin
42. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
43. Bactericidal antibody recognition of meningococcal PorA by induced fit
44. Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis
45. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis
46. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitidis serogroup B are prerequisites for virulence of meningococci in the infant rat
47. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis
48. Functional characterization of an isogenic meningococcal a-2,3-sialyltransferase mutant: The role of lipooligosaccharide for serum resistance in serogroup B meningococci
49. Mechanisms of neisserial serum resistance
50. Immunologic response of man to group B meningococcal polysaccharide vaccine